Literature DB >> 12610007

Trends in the diabetes quality improvement project measures in Maine from 1994 to 1999.

Monica R McClain1, David E Wennberg, Roger W Sherwin, William C Steinmann, Janet C Rice.   

Abstract

OBJECTIVE: To examine changes in the management of patients with diabetes from 1994 to 1999 using the claims-based Diabetes Quality Improvement Project (DQIP) accountability measures. RESEARCH DESIGN AND METHODS: Administrative claims from an employer-based health insurance cohort in Maine were used to describe the prevalence of claims-based DQIP accountability measures-HbA(1c) testing, dilated eye examination, lipid profile, and monitoring for diabetic nephropathy-from 1994 (n = 1151) to 1999 (n = 2221) in a 100% sample of adults (18-64 years of age) with diabetes. The Mantel-Haenszel chi(2) test for trend was performed on each measure. Prevalence estimates were also stratified by three insurance products: health maintenance organization (HMO), point of service, and indemnity.
RESULTS: There was a positive trend for all outcome measures (P < 0.001). The baseline and final frequencies (percent increase) for lipid testing, HbA(1c), dilated eye examination, and screening for diabetic nephropathy were as follows: 13-50% (257%), 37-69% (92%), 30-46% (53%), and 37-50% (36%), respectively. Individuals with diabetes and indemnity insurance were much less likely to receive these measures than individuals with other types of insurance, whereas people in HMOs were more likely to receive HbA(1c) testing and lipid profiles.
CONCLUSIONS: The proportion of patients with diabetes receiving DQIP accountability measures significantly increased from 1994 to 1999. There is large variation in prevalence among these measures and insurance products. It is urgent to identify effective mechanisms for delivering consistent preventive care that are congruent with defined standards of benefit.

Entities:  

Mesh:

Year:  2003        PMID: 12610007     DOI: 10.2337/diacare.26.3.597

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

Review 1.  Provider and systems factors in diabetes quality of care.

Authors:  Kimia Ghaznavi; Shaista Malik
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

Review 2.  Health systems, patients factors, and quality of care for diabetes: a synthesis of findings from the TRIAD study.

Authors: 
Journal:  Diabetes Care       Date:  2010-04       Impact factor: 17.152

3.  Missed opportunities in diabetes management: a longitudinal assessment of factors associated with sub-optimal quality.

Authors:  T Alafia Samuels; Shari Bolen; H C Yeh; Marcela Abuid; Spyridon S Marinopoulos; Jonathan P Weiner; Maura McGuire; Frederick L Brancati
Journal:  J Gen Intern Med       Date:  2008-09-12       Impact factor: 5.128

4.  Effect of advanced access scheduling on processes and intermediate outcomes of diabetes care and utilization.

Authors:  Usha Subramanian; Ronald T Ackermann; Edward J Brizendine; Chandan Saha; Marc B Rosenman; Deanna R Willis; David G Marrero
Journal:  J Gen Intern Med       Date:  2009-01-09       Impact factor: 5.128

5.  Process of care compliance is associated with fewer diabetes complications.

Authors:  Felicia J Bayer; Deron Galusha; Martin Slade; Isabella M Chu; Oyebode Taiwo; Mark R Cullen
Journal:  Am J Manag Care       Date:  2014       Impact factor: 2.229

6.  No consistent association between processes-of-care and health-related quality of life among patients with diabetes: a missing link?

Authors:  Alejandra Casillas; Katia Iglesias; Aline Flatz; Bernard Burnand; Isabelle Peytremann-Bridevaux
Journal:  BMJ Open Diabetes Res Care       Date:  2015-01-10

7.  Association Between Routine Nephropathy Monitoring and Subsequent Change in Estimated Glomerular Filtration Rate in Patients With Diabetes Mellitus: A Japanese Non-Elderly Cohort Study.

Authors:  Sachiko Ono; Yosuke Ono; Daisuke Koide; Hideo Yasunaga
Journal:  J Epidemiol       Date:  2019-06-15       Impact factor: 3.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.